Zoetis Inc. (ZTS)
| Bid | 150.64 |
| Market Cap | 67.51B |
| Revenue (ttm) | 9.26B |
| Net Income (ttm) | 2.49B |
| EPS (ttm) | 5.47 |
| PE Ratio (ttm) | 27.56 |
| Forward PE | 26.65 |
| Analyst | Buy |
| Ask | 150.98 |
| Volume | 2,193,230 |
| Avg. Volume (20D) | 3,121,108 |
| Open | 151.66 |
| Previous Close | 149.44 |
| Day's Range | 147.99 - 152.33 |
| 52-Week Range | 139.70 - 200.33 |
| Beta | 0.93 |
About ZTS
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respirat...
Analyst Forecast
According to 9 analyst ratings, the average rating for ZTS stock is "Buy." The 12-month stock price forecast is $225, which is an increase of 49.24% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago · seekingalpha.com
Zoetis: Lots Of Growth Opportunities For This High-Quality CompounderZoetis is currently cheap from a historical perspective, presenting a potential buying opportunity. The company operates in a growing animal healthcare market, benefiting from trends like pet humaniza...
